First real-world insights on benefit of apremilast treatment in patients with moderate to severe psoriasis after switching from fumaric acid esters from the APART Study - an interim analysis

Conference contribution


Publication Details

Author(s): Mrowietz U, Ertner K, Sticherling M, Grosse V, Popp G, Roemmler-Zehrer J, Lampl M, Helget U, Gomez NN
Publisher: WILEY
Publishing place: HOBOKEN
Publication year: 2019
Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Pages range: 123-123
ISSN: 1610-0387
eISSN: 1610-0379


FAU Authors / FAU Editors

Sticherling, Michael Prof. Dr.
Professur für Dermatologie


External institutions with authors

Celgene GmbH
licca Klinik für operative Medizin
Universitätsklinikum Schleswig-Holstein (UKSH)


How to cite

APA:
Mrowietz, U., Ertner, K., Sticherling, M., Grosse, V., Popp, G., Roemmler-Zehrer, J.,... Gomez, N.N. (2019). First real-world insights on benefit of apremilast treatment in patients with moderate to severe psoriasis after switching from fumaric acid esters from the APART Study - an interim analysis. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 123-123). HOBOKEN: WILEY.

MLA:
Mrowietz, U., et al. "First real-world insights on benefit of apremilast treatment in patients with moderate to severe psoriasis after switching from fumaric acid esters from the APART Study - an interim analysis." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2019. 123-123.

BibTeX: 

Last updated on 2019-28-05 at 15:38